Zymeworks share price logo

Zymeworks

NASDAQ: ZYME

Mid Cap

$28.61

-0.10

(-0.35%)

as on

Zymeworks Stock Performance

as on October 31, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $28.26
    $29.01
    downward going graph

    1.22%

    Downside

    1.40%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $16.00
    $31.34
    downward going graph

    44.06%

    Downside

    9.54%

    Upside

    downward going graph

Zymeworks share price movements today

Previous Close
$28.71
Open
$28.71
Volume
603.7K
Market Cap
$2.1B
Day's Low - High
$28.26 - $29.01
52 Week Low - High
$16.00 - $31.34

Zymeworks Historical Returns

1 Month Return
+ 8.38 %
3 Month Return
+ 26.42 %
1 Year Return
+ 50.16 %
3 Year Return
+ 310.73 %
5 Year Return
+ 29.03 %

Zymeworks Stock Fundamentals & Key Indicators

Check Zymeworks market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.1B

EPS (TTM)

-2.02

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-14.31

Industry PE ratio

-7.01

PEG Ratio

0.21

EBITDA

-140.2M

Revenue (TTM)

37.1M

Profit Margin

87.78%

Return On Equity TTM

-72.07%

Zymeworks vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Zymeworks with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$2.1B29.03%-14.3187.78%0.00%
Neutral$85.5B-35.47%-26.84-12.57%0.00%
StrongBuy$134.2B192.00%30.5886.04%0.00%
Buy$83.7B27.94%19.4284.86%0.45%

Stock Returns calculator for Zymeworks Stock including INR - Dollar returns

The Zymeworks stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Zymeworks investment value today

Current value as on today

₹1,60,054

Returns

₹60,054

(+60.05%)

Returns from Zymeworks Stock

₹49,634 (+49.63%)

Dollar Impact

₹10,420 (+10.42%)

Analyst Recommendation on Zymeworks Stock

Based on 12 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 12 analysts, 100% of analysts recommend a 'BUY' rating for Zymeworks. Average target price of $41.43

Zymeworks Share Price Target

Get share price movements and forecasts by analysts on Zymeworks.

What analysts predicted

30.94%UPSIDE

Target Price

$41.43

Current Price

$28.61

Analyzed by

12 Analysts

High

$55

Target

$41.43

Low

$33

Zymeworks target price $41.43, a slight upside of 30.94% compared to current price of $28.61. According to 12 analysts rating.

Indian Investors' Interest in Zymeworks Stock

Search interest for Zymeworks Stock has decreased by -65% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-65% versus previous 30 day period

Zymeworks Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
10
19
16
31
27
48
27
2
2
4
Gross Profit
10
19
16
31
27
48
27
0
0
4
Operating Income
-37
-42
-34
-22
-25
0
-22
-44
-47
-42
EBITDA
-20
-23
-31
-18
-22
2
-15
-39
-41
-43
Interest Expense
-
-
-
-
-
-
-
-
2
-
Depreciation
2
2
2
3
3
3
2
1
2
1
Income Before Tax
-31
-37
-29
-17
-22
2
-18
-41
-46
-45
Income Tax Expense
0
0
0
5
0
0
1
0
-2
0
Net Income
-31
-37
-29
-23
-22
2
-19
-41
-44
-45
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
32.76%
-18.23%
100.00%

Zymeworks Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
51
53
29
38
26
412
76
76
105
Gross Profit
10
-3
-87
-131
26
412
-66
76
105
Operating Income
-8
-33
-151
-187
-215
130
-138
-137
-92
EBITDA
-6
-30
-143
-176
-206
142
-120
-108
-68
Interest Expense
1
0
-
-
-
-
-
-
-
Depreciation
2
3
7
10
9
12
17
11
11
Income Before Tax
-9
-34
-144
-180
-212
135
-119
-116
-79
Income Tax Expense
0
2
0
0
0
10
0
6
1
Net Income
-10
-36
-145
-180
-211
124
-118
-122
-81
Net Profit Margin
20.51%
-7.37%
-296.34%
-338.75%
100.00%
100.00%
-88.11%
100.00%
100.00%

Zymeworks Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-31
-37
-29
-23
-22
2
-19
-41
-44
-45
Operating Cash Flow
-37
-24
-5
-41
-3
12
-31
-9
-45
-31
Investing Cash Flow
-7
-19
72
-6
12
8
0
5
69
17
Financing Cash Flow
2
1
-14
-8
1
1
-2
-18
178
-50
Change in Cash
-42
-43
51
-56
10
22
-33
-23
203
-64

Zymeworks Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-10
-36
-145
-180
-211
124
-118
-122
-81
Operating Cash Flow
0
24
-81
-151
-192
144
-118
-110
-33
Investing Cash Flow
-30
-109
-25
-43
144
-53
-207
38
26
Financing Cash Flow
49
91
193
308
8
108
81
-20
-18
Change in Cash
19
6
86
113
-40
199
-243
-91
-24

Global Institutional Holdings in Zymeworks

Check out the Institutions with significant holdings in Zymeworks.

Funds
Holdings
Joseph Edelman
5.89%
iShares
3.56%
Vanguard
2.80%
VANGUARD INDEX FUNDS
2.13%
IVY FUNDS
0.85%

Zymeworks News & Key Events

  • img

    Today's Timeline - 25 October

    Mon, 02:15 AM

    -

    Zymeworks presents Phase 1 study data for ZW191, showing promising anti-tumor activity in platinum-resistant ovarian cancer patients.

Insights on Zymeworks

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 2.40M → 4.59M (in $), with an average increase of 47.5% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ZYME has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, ZYME stock has moved up by 30.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 720.2% return, outperforming this stock by 669.8%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 5 quarters, 2.31M → -45.01M (in $), with an average decrease of 266.3% per quarter

About Zymeworks

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
OrganisationZymeworks
Headquarters108 Patriot Drive, Middletown, DE, 19709, US
IndustryBiotechnology
CEOKenneth H. Galbraith

Key Management of Zymeworks

Name

Title

Mr. Kenneth H. Galbraith C.A.

Chairman of the Board, CEO & President

Dr. Paul A. Moore Ph.D.

Chief Scientific Officer

Mr. Scott Platshon B.S.

Executive VP & Chief Business Officer

Mr. Mark Hollywood

Executive VP & COO

FAQs

What is Zymeworks share price today?

Zymeworks share price today is $28.61 as on at the close of the market. Zymeworks share today touched a day high of $29.01 and a low of $28.26.

What is the 52 week high and 52 week low for Zymeworks share?

Zymeworks share touched a 52 week high of $31.34 on and a 52 week low of $16.00 on . Zymeworks stock price today i.e. is closed at $28.61,which is 8.71% down from its 52 week high and 78.77% up from its 52 week low.

What is Zymeworks's market capitalisation today?

Zymeworks market capitalisation is $0.00T as on .

How to invest in Zymeworks Stock (ZYME) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Zymeworks on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Zymeworks Stock (ZYME) from India?

Indian investors can start investing in Zymeworks (ZYME) shares with as little as ₹94.94999694824219 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.50 in Zymeworks stock (as per the Rupee-Dollar exchange rate as on ). Based on Zymeworks share’s latest price of $28.61 as on October 31, 2026 at 8:46 am IST, you will get 0.3495 shares of Zymeworks. Learn more about fractional shares .

What are the returns that Zymeworks has given to Indian investors in the last 5 years?

Zymeworks stock has given 29.03% share price returns and 27.26% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?